Latest Insider Transactions at Arrowhead Pharmaceuticals, Inc. (ARWR)
This section provides a real-time view of insider transactions for Arrowhead Pharmaceuticals, Inc. (ARWR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ARROWHEAD PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ARROWHEAD PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 03
2023
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
10,338
-0.85%
|
$403,182
$39.05 P/Share
|
|
Dec 29
2022
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
30,625
-8.34%
|
$1,225,000
$40.0 P/Share
|
|
Dec 21
2022
|
Patrick O'Brien COO and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+7.75%
|
$192,000
$6.15 P/Share
|
|
Dec 20
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
234,025
+5.92%
|
-
|
|
Dec 16
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
18,375
+0.52%
|
-
|
|
Nov 21
2022
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,500
-8.8%
|
$585,000
$30.3 P/Share
|
|
Sep 27
2022
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Exercise of conversion of derivative security
|
Direct |
40,624
-0.58%
|
$1,218,720
$30.99 P/Share
|
|
Jul 08
2022
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
551,197
-13.58%
|
-
|
|
Jul 07
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,501
+0.06%
|
$35,014
$14.54 P/Share
|
|
Feb 11
2022
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
146,388
-0.88%
|
$7,465,788
$51.7 P/Share
|
|
Feb 11
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
146,388
+3.36%
|
$731,940
$5.19 P/Share
|
|
Jan 07
2022
|
Marianne De Backer Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+21.48%
|
-
|
|
Jan 07
2022
|
Mauro Ferrari Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+12.96%
|
-
|
|
Jan 07
2022
|
Douglas B Given Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+5.22%
|
-
|
|
Jan 07
2022
|
Adeoye Y Olukotun Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+36.06%
|
-
|
|
Jan 07
2022
|
Michael S Perry Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+6.51%
|
-
|
|
Jan 07
2022
|
William D. Waddill Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,400
+16.6%
|
-
|
|
Jan 07
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,806
+0.29%
|
$59,030
$5.19 P/Share
|
|
Jan 05
2022
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
32,500
-1.76%
|
$2,015,000
$62.59 P/Share
|
|
Jan 05
2022
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
40,000
-2.04%
|
$2,480,000
$62.41 P/Share
|
|
Jan 05
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
6,250
-0.78%
|
$387,500
$62.6 P/Share
|
|
Jan 04
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
19,375
-2.21%
|
$1,298,125
$67.07 P/Share
|
|
Jan 03
2022
|
Michael S Perry Director |
SELL
Open market or private sale
|
Direct |
4,500
-1.69%
|
$292,500
$65.22 P/Share
|
|
Jan 03
2022
|
Marianne De Backer Director |
SELL
Open market or private sale
|
Direct |
4,500
-7.44%
|
$292,500
$65.17 P/Share
|
|
Jan 03
2022
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
4,050
-17.55%
|
$263,250
$65.18 P/Share
|
|
Jan 03
2022
|
William D. Waddill Director |
SELL
Open market or private sale
|
Direct |
4,500
-5.18%
|
$292,500
$65.16 P/Share
|
|
Jan 01
2022
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+16.51%
|
-
|
|
Jan 01
2022
|
Kenneth Allen Myszkowski Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+10.64%
|
-
|
|
Jan 01
2022
|
James C Hamilton Chief Discovery/Trans Medicine |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+23.28%
|
-
|
|
Jan 01
2022
|
Patrick O'Brien COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+13.59%
|
-
|
|
Dec 31
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
28,000
+8.01%
|
$168,000
$6.15 P/Share
|
|
Dec 28
2021
|
Mauro Ferrari Director |
SELL
Open market or private sale
|
Direct |
3,400
-8.51%
|
$224,400
$66.82 P/Share
|
|
Dec 28
2021
|
Douglas B Given Director |
BUY
Open market or private purchase
|
Direct |
655
+0.59%
|
$43,230
$66.37 P/Share
|
|
Dec 28
2021
|
Douglas B Given Director |
SELL
Bona fide gift
|
Direct |
655
-0.6%
|
-
|
|
Dec 23
2021
|
Christopher Richard Anzalone Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,806
+0.36%
|
$59,030
$5.19 P/Share
|
|
Dec 15
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
60,000
-0.37%
|
$4,080,000
$68.28 P/Share
|
|
Nov 19
2021
|
Martin Javier San Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
19,500
-5.16%
|
$1,365,000
$70.0 P/Share
|
|
Oct 22
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
50,000
-0.75%
|
$3,250,000
$65.83 P/Share
|
|
Oct 20
2021
|
Christopher Richard Anzalone Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,000
-0.45%
|
$990,000
$66.23 P/Share
|
|
Sep 13
2021
|
Adeoye Y Olukotun Director |
SELL
Open market or private sale
|
Direct |
5,000
-19.74%
|
$315,000
$63.76 P/Share
|
|
Sep 09
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
5,000
-4.35%
|
$325,000
$65.24 P/Share
|
|
Jun 24
2021
|
Marianne De Backer Director |
SELL
Open market or private sale
|
Direct |
5,000
-18.87%
|
$445,000
$89.85 P/Share
|
|
Jun 22
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Direct |
4,500
-3.77%
|
$400,500
$89.21 P/Share
|
|
Jun 22
2021
|
James Hassard Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,625
-3.31%
|
$322,625
$89.22 P/Share
|
|
Feb 22
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
1,125
-7.5%
|
$99,000
$88.73 P/Share
|
|
Feb 08
2021
|
Patrick O'Brien COO and General Counsel |
SELL
Open market or private sale
|
Direct |
90,000
-6.35%
|
$7,920,000
$88.34 P/Share
|
|
Feb 08
2021
|
Patrick O'Brien COO and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
90,000
+19.01%
|
$450,000
$5.22 P/Share
|
|
Jan 15
2021
|
Douglas B Given Director |
SELL
Open market or private sale
|
Indirect |
3,000
-19.35%
|
$249,000
$83.28 P/Share
|
|
Jan 14
2021
|
James C Hamilton Chief Discovery/Trans Medicine |
SELL
Open market or private sale
|
Direct |
10,000
-3.74%
|
$810,000
$81.4 P/Share
|
|
Jan 12
2021
|
Kenneth Allen Myszkowski Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,441
-0.32%
|
$116,721
$81.0 P/Share
|